SCNX

0.839

3.31% -0.0287

Dopo l'orario di chiusura: .82 -0.019 -2.26%

Scienture Holdings Inc (SCNX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$0.8677

Aprire:

$0.8596

Volume 24 ore:

92,473

Relative Volume:

0.04

Capitalizzazione di mercato:

$7.91M

Reddito:

Utile/perdita netta:

Rapporto P/E:

EPS:

Flusso di cassa netto:

1 W Prestazione:

-4.66%

1M Prestazione:

-58.26%

6M Prestazione:

-87.48%

1 anno Prestazione:

+0.00%

Intervallo 1D:

$0.8178

$0.90

Intervallo di 1 settimana:

$0.8178

$0.9758

Portata 52W:

$0.69

$9.55

Scienture Holdings Inc Stock (SCNX) Company Profile

Nome

Scienture Holdings Inc

Settore

Healthcare (1182)

Industria

Pharmaceutical Retailers (11)

Telefono

(800) 261 0281

Indirizzo

2420 BRUNELLO TRACE, LUTZ

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

SCNX's Discussions on Twitter

Confronta SCNX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SCNX Scienture Holdings Inc	0.839	7.91M	0	0	0	0.00
WBA Walgreens Boots Alliance Inc	10.87	9.43B	147.66B	-8.64B	-363.00M	-10.01
WGRX Wellgistics Health Inc	3.10	198.95M	0	0	0	0.00
HITI High Tide Inc	2.31	165.11M	376.07M	-22.41M	18.73M	-0.298
PETS Petmed Express Inc	3.16	62.38M	270.52M	-6.08M	17.42M	-0.2944
HKPD Hong Kong Pharma Digital Technology Holdings Ltd	0.9337	13.97M	0	0	0	0.00

Scienture Holdings Inc Borsa (SCNX) Ultime notizie

Apr 11, 2025

Scienture Holdings Divests Subsidiaries to Tollo Health - MSN

Apr 11, 2025

Apr 08, 2025

Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa

Apr 08, 2025

Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks

Apr 08, 2025

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times

Apr 08, 2025

Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan

Apr 08, 2025

Apr 05, 2025

SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com

Apr 04, 2025

SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 03, 2025

Scienture Holdings gears up for specialty pharma launches - Investing.com

Apr 03, 2025

Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks

Apr 03, 2025

Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK

Apr 03, 2025

Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView

Apr 03, 2025

Mar 26, 2025

Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register

Mar 26, 2025

Mar 25, 2025

Scienture Bolsters Commercial Operations with New Leadership and Syneos Health Partnership - AInvest

Mar 25, 2025

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times

Mar 25, 2025

Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan

Mar 25, 2025

3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail

Mar 25, 2025

Mar 21, 2025

Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks

Mar 21, 2025

Mar 20, 2025

Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail

Mar 20, 2025

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 19, 2025

Scienture Holdings announces draw on Equity Line of Credit - MSN

Mar 19, 2025

Scienture announces draaw on Equity Line of Credit - TipRanks

Mar 19, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times

Mar 19, 2025

Organovo Announces Reverse Stock Split - The Manila Times

Mar 19, 2025

FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan

Mar 19, 2025

Mar 18, 2025

Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Mar 18, 2025

FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics

Mar 18, 2025

What's Going On With Scienture Shares Tuesday? - Benzinga

Mar 18, 2025

FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times

Mar 18, 2025

Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph

Mar 18, 2025

Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - MarketScreener

Mar 18, 2025

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Mar 18, 2025

Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan

Mar 18, 2025

Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail

Mar 18, 2025

Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail

Mar 18, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 17, 2025

Mar 15, 2025